1-butyl-3-methylimidazolium dicyanamide

We are 1-butyl-3-methylimidazolium dicyanamide CAS:448245-52-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


English Name: 1-butyl-3-methylimidazolium dicyanamide
Synonyms:1-butyl-3-methylimidazol-3-ium,cyanoiminomethylideneazanide
Molecular Formula: C10H15N5
Molecular Weight: 205.26
CAS No.: 448245-52-1
Purity: 99%
 
Technical Information

Appearance:	Purity:
NMR: Passed	null
Solubility:	Insolubility:
Impurity content: (1) Methylimidazole content: < 1000 ppm; (2) Halogen content: < 1000 ppm; (3) Water content: < 1000 ppm

 
Physics-Chemistry Properties

Melting point: -6℃	Decomposition temperature: 300℃
Conductivity: 8.9ms/cm	Electrochemical window:
Viscosity: 37cp	Density: 1.06 g/cm3

 
Our company has been engaged in the R&D, production of ionic liquids and related technologies for more than ten years. Since 2007, our company has supplied ionic liquid reagents to customers, and can provide customers with ionic liquid products from grams to hundreds of tons. The main product series are: Imidazolium ionic liquids, single-substituted Im ionic liquids, Disubstituted Im ionic liquids, Tri-Substituted Im ionic liquids, Pyrilidinium ionic liquids, Ammonium ionic liquids, Phosphonium ionic liquids, Pyrrolidinium ionic liquids, Piperidinium ionic liquids, Functionized ionic liquids, Vinyl-Based ionic liquids, Hydroxyl-Based ionic liquids, Ether-Based ionic liquids, Ester-Based ionic liquids, Carboxyl-Based ionic liquids, Nitrile-Based ionic liquids, Amido-Based ionic liquids, SulfoAcid-Based ionic liquids, Benzyl-Based ionic liquids, Guanidine-Based ionic liquids, Oxonium salts



Related News: As United Airlines said when suspended flights to Beijing, Shanghai and Chengdu, the decision was made “due to the continued drop in demand for travel to China and the US Department of State’s decision to raise its China travel advisory to a Level 4.”3543-73-5 “This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment,” Mankind Pharma Director of Marketing Sanjay Koul said in a statement.35905-85-2 “This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment,” Mankind Pharma Director of Marketing Sanjay Koul said in a statement.tereftalato de mono-metilo CAS:1679-64-7 China’s pharmaceutical CMO market has recently maintained a growth rate of more than 10%. From the perspective of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7%.But they’ll be subject to up to 14 days of mandatory quarantine once they’re back in the US.